ZAI Lab

Zai Lab is teaming up with MacroGenics a second time, after their initial 2018 collaboration, on four bispecific antibodies. The deal comes two months after Zai said it would offer $750 million in American depository shares to fund business and product development as well as deals.

Led by Samantha Du, Ph.D., who is viewed by many as the godmother of China's biotech industry, Zai Lab has made a name for itself by bringing new drugs from the likes of GlaxoSmithKline and Regeneron into the country. Now, the company is looking for more cash to ink yet more licensing deals--and it's tapping into U.S. investors.

/PRNewswire/ -- Forbes today released the 2021 Midas List, a ranking of the world's top 100 venture capitalists. Duane Kuang and Nisa Leung, Managing Partners...

/PRNewswire/ -- Qiming Venture Partners ("Qiming") today announced the final close of our RMB Fund VI at RMB 2.852 billion. Currently, Qiming has $5.9 billion...

Zai Lab is looking to boost its cancer credentials and pipeline with the appointment of Roche oncology vet Alan Sandler, M.D.

Although biopharma executives leave for many reasons and at any time, there is a tendency to make shifts toward the end of the year. Today there were two high-profile announcements to start off the month of December.